Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study.
Saved in:
| Title: | Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study. |
|---|---|
| Authors: | Ravi V; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Subramaniam A; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Zheng J; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Amini B; Musculoskeletal Imaging Department, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Trinh VA; Department of Clinical Pharmacy Services, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Joseph J; Department of Clinical Pharmacy Services, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Mennel RG; Texas Oncology-Baylor Charles A. Sammons Center, Dallas, Texas, USA., Bishop AJ; Radiation Oncology Department, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Sturgis EM; Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas, USA., Goepfert RP; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Yalamanchili S; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Botello G; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Stephen B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Patel AB; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Lazar AJ; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Conley AP; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Benjamin RS; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Patel SR; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Futreal PA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Somaiah N; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. |
| Source: | Cancer [Cancer] 2022 Sep 15; Vol. 128 (18), pp. 3383-3391. Date of Electronic Publication: 2022 Jul 06. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1097-0142 |
|---|---|
| DOI: | 10.1002/cncr.34370 |
